Protect Pharmaceutical (PRTT) 10-Q 2015 Q3 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended September 30, 2015

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____  to ______

Commission File Number 000-54001

PROTECT PHARMACEUTICAL CORPORATION

(Exact name of registrant as specified in its charter)

Nevada	27-1877179
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

2681 Parleys Way, Suite 204, Salt Lake City, UT 84109

(Address of principal executive offices)

(801) 322-3401

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  

Yes  ¨    No  x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company

Large accelerated filer         ¨	Accelerated filer                        ¨
Non-accelerated filer           ¨	Smaller reporting company      x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 

Yes  ¨    No  x

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.

Class	Outstanding as of November 16, 2015
Common Stock, $0.005 par value	1,111,460

TABLE OF CONTENTS

Heading		Page
	PART  I— FINANCIAL INFORMATION
Item 1.	Unaudited Financial Statements	3
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	10
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	13
	PART II— OTHER INFORMATION
Item 1.	Legal Proceedings	14
Item 1A.	Risk Factors	14
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.	Defaults Upon Senior Securities	14
Item 4.	Mine Safety Disclosures	14
Item 5.	Other Information	14
Item 6.	Exhibits	14
	Signatures	15

1

PART  I   —   FINANCIAL INFORMATION

Item 1.  Financial Statements

The accompanying unaudited balance sheets of Protect Pharmaceutical Corporation at September 30, 2015 and related unaudited statements of operations and cash flows for the three and nine months ended September 30, 2015 and 2014, have been prepared by management in conformity with United States generally accepted accounting principles.   In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.  We suggest that these financial statements be read in conjunction with the audited financial statements and notes thereto included in the company’s December 31, 2014 Form 10-K.  Operating results for the period ended September 30, 2015, are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2015 or any other subsequent period.

PROTECT PHARMACEUTICAL CORPORATION
Balance Sheets
ASSETS
			September 30,		December 31,
			2015		2014
			(Unaudited)
CURRENT ASSETS
	Cash		$	164	$	502
		Total Current Assets		164		502
		TOTAL ASSETS	$	164	$	502
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
	Accounts payable and accrued expenses		$	66,901	$	61,053
	Accounts payable - related parties			-		2,380
	Related party payables			28,638		58,052
		Total Current Liabilities		95,539		121,485
		TOTAL LIABILITIES		95,539		121,485
STOCKHOLDERS' DEFICIT
	Preferred stock; 10,000,000 shares authorized,
	at $0.001 par value, no shares issued or outstanding			-		-
	Common stock; 100,000,000 shares authorized,
	at $0.005 par value, 1,111,460 and 89,459
	shares issued and outstanding, respectively			5,557		447
	Additional paid-in capital			9,242,788		8,593,398
	Deficit accumulated during the development stage			(9,343,720)		(8,714,828)
		Total Stockholders' Deficit		(95,375)		(120,983)
		TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	164	$	502
The accompanying notes are an integral part of these condensed financial statements.

PROTECT PHARMACEUTICAL CORPORATION
Statements of Operations
(Unaudited)
		For the Three Months Ended				For the Nine Months Ended
		September 30,				September 30,
		2015		2014		2015		2014
REVENUES		$	-	$	-	$	-	$	-
EXPENSES
	Professional Fees		7,305		5,840		17,094		14,965
	Executive compensation		1,500		1,500		4,500		4,500
	General and administrative		1,650		48		1,861		137
LOSS FROM OPERATIONS			(10,455)		(7,388)		(23,455)		(19,602)
OTHER EXPENSES
	Loss on settlement of debt		(605,437)		-		(605,437)		-
LOSS BEFORE INCOME TAXES			(615,892)		(7,388)		(628,892)		(19,602)
	Income Taxes		-		-		-		-
NET LOSS		$	(615,892)	$	(7,388)	$	(628,892)	$	(19,602)
BASIC AND DILUTED LOSS PER SHARE OF
	COMMON STOCK	$	(1.43)	$	(0.13)	$	(2.91)	$	(0.40)
WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING			430,141		56,160		215,792		48,478
The accompanying notes are an integral part of these condensed financial statements.

PROTECT PHARMACEUTICAL CORPORATION
Statements of Cash Flows
(Unaudited)
			For the Nine Months Ended
			September 30,
			2015		2014
OPERATING ACTIVITIES
	Net loss		$	(628,892)	$	(19,602)
Adjustments to reconcile net loss
to cash flows from operating activities
	Services contributed by an officer			4,500		4,500
	Expenses paid on behalf of the Company			-		11,499
	Loss on settlement of debt			605,437		-
Changes in operating assets and liabilities
	Accounts payable			5,847		4,001
	Accounts payable - related parties			(2,380)		(533)
		Net Cash Provided by (Used in)
		Operating Activities		(15,488)		(135)
INVESTING ACTIVITIES				-		-
FINANCING ACTIVITIES
	Proceeds from notes payable - related parties			15,150		-
		Net Cash Provided by Financing Activities		15,150		-
NET CHANGE IN CASH				(338)		(135)
CASH AT BEGINNING OF PERIOD				502		681
CASH AT END OF PERIOD			$	164	$	546
SUPPLEMENTAL CASH FLOW INFORMATION:
	NON-CASH FINANCING ACTIVITIES:
		Common shares issued for rounding
		pursuant to reverse stock-split	$	110	$	-
		Capital contributed for accounts payable -
		related parties	$	-	$	10,000
		Common Stock issued for
		Settlement of debt	$	650,000	$	-
The accompanying notes are an integral part of these condensed financial statements.

5

PROTECT PHARMACEUTICAL CORPORATION

Notes to Condensed Financial Statements

September 30, 2015 and December 31, 2014

(Unaudited)

 NOTE 1 - CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2015, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2014 audited financial statements.  The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of the operating results for the full years.

NOTE 2 - GOING CONCERN

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern.  It is the intent of the Company to seek a merger with an existing, operating company.  In the interim, shareholders of the Company have committed to meeting its minimal operating expenses

 NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Basic (Loss) per Common Share

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of September 30, 2015 and 2014.

6

PROTECT PHARMACEUTICAL CORPORATION

Notes to Condensed Financial Statements

September 30, 2015 and December 31, 2014

(Unaudited)

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recent Accounting Pronouncements

Management has considered all other recent accounting pronouncements issued since the last audit of the Company’s financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements.

NOTE 4 – RELATED-PARTY TRANSACTIONS

The Company has recorded advances from related parties and expenses paid by an entity controlled by a Company officer and by a shareholder on behalf of the Company as related party payables. As of September 30, 2015 and December 31, 2014, respectively, the related party payable outstanding balance totaled $28,638 and $58,052, respectively. These payables are non-interest bearing, unsecured, and are due on demand.

Common Stock Issued for Related-Party Debt

On September 1, 2015 the Company issued an aggregate of 1,000,000 shares of common stock to related parties as payment on a note payable with a balance of $44,563.  The shares were valued at $0.65 per share, resulting in a total payment value of $650,000.  The transaction resulted in the Company recorded a loss on settlement of debt in the amount of $605,437.

Contributed Capital

During the nine months ended September 30, 2015 and 2014, the Company’s director and sole officer has contributed various administrative services to the Company. These services havebeen valued at $4,500 for theninemonth periods then ended.  In addition, during the year ended December 31, 2014 a related-party entity paid $10,000 toward accounts payable related parties held by the Company.

NOTE 5 – STOCKHOLDERS’ EQUITY

On September 19, 2014, the Company issued 26,000 shares of common stock to Blue Cap Development Corp. in exchange for certain mining and/or mineral claims and/or leases located in New Mexico. Two principals of Blue Cap, Edward F. Cowle and H. Deworth Williams, are principal stockholders of the Company.

On November 4, 2014, the Company affected a reverse stock split of its issued and outstanding shares of common stock on a one (1) share for one thousand (1,000) shares basis. As per the terms of the reverse stock split, any fractional share amount resulting from the split was automatically rounded up to the next higher whole share amount, with the provision that no individual stockholder’s holdings would be reduced below 100 shares. Additional shares to restore each such affected stockholder’s holdings to 100 shares were issued, with certain shares issued during the 2014 calendar year, and the remainder issued during the nine months ended September 30, 2015.  The par value of the common stock remains at $0.005 per share.

7

PROTECT PHARMACEUTICAL CORPORATION

Notes to Condensed Financial Statements

September 30, 2015 and December 31, 2014

(Unaudited)

NOTE 5 – STOCKHOLDERS’ EQUITY (Continued)

On September 1, 2015 the Company issued an aggregate of 1,000,000 shares of common stock to related parties as payment on a note payable with a balance of $44,563.  The shares were valued at $0.65 per share, resulting in a total payment value of $650,000.  The transaction resulted in the Company recorded a loss on settlement of debt in the amount of $605,437.

NOTE 6 – SUBSEQUENT EVENTS

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following information should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in this Form 10-Q.

Forward-Looking and Cautionary Statements

This report contains forward-looking statements relating to future events or our future financial performance.  In some cases, you can identify forward-looking statements by terminology such as “may,” “will” “should," “expect," "intend," "plan," anticipate," "believe," "estimate," "predict," "potential," "continue," or similar terms, variations of such terms or the negative of such terms.  These statements are only predictions and involve known and unknown risks, uncertainties and other factors included in our periodic reports with the SEC.  Although forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment, actual results could differ materially from those anticipated in such statements.  Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Recent Events

Conversion of Notes

On September 1, 2015, upon the conversion of a certain Amended Promissory Note dated August 20, 2015 (the “Note”) in the amount of $44,563, including principal and interest, the company issued to two persons an aggregate of 1,000,000 shares of the company’s authorized, but previously common stock.  The exercise price of the Note was $0.046 per share pursuant to the negotiated terms of the Note. The Note represents funds advanced to the company, debts incurred by and expenses paid on behalf of the company.  The Note is an amendment to the original promissory note dated January 21, 2015 and an addendum dated February 11, 2015.

The shares were issued pursuant to a private, isolated transaction to a related party and another individual, familiar with and having knowledge of our business.  In issuing the shares, the company relied on the exemption from registration under the Securities Act of 1933 provided by Section 4(a)(2) of that Act.  

Following the issuance of the above shares, the company presently has issued and outstanding 1,111,460 shares of common stock. All share references in this report reflect the one share for one thousand shares reverse split effected on November 4, 2014.

Results of Operations

Three Months Ended September 30, 2015 and 2014

The company did not realize revenues for the three-month periods ended September 30, 2015 and 2014. During the three months ended September 30, 2015 (“third quarter”), we recorded total operating expenses of $10,455, consisting of $7,305 in professional fees, $1,500 in executive compensation and $1,650 in general and administrative expenses. In the comparable third quarter of 2014, we recorded operating expenses totaling $7,388, consisting of $5,840 in professional fees, $1,500 in executive compensation and $48 in general and administrative expenses.  The increase in operating expenses during the third quarter of 2015 was due primarily to the increase in professional fees related to the company’s ongoing reporting obligations with the SEC. We also recorded a $605,437 loss on the settlement of debt during the third quarter of 2015 related to the issuance of common stock pursuant to the conversion of the Note discussed above by a related party. Collectively, these factors resulted in a net loss for the third quarter ended September 30, 2015 in the amount of $615,892 ($1.43 per share), compared to net loss of $7,388 ($0.13 per share) for the third quarter ended September 30, 2014.

Nine Months Ended September 30, 2015 and 2014

We did not realize revenues for the nine-month periods ended September 30, 2015 and 2014. During the nine months ended September 30, 2015 we recorded total operating expenses of $23,455, consisting of $17,094 in professional fees, $4,500 in executive compensation and $1,861 in general and administrative expenses. In the comparable nine month period of 2014, we recorded operating expenses totaling $19,602, consisting of $14,965 in professional fees, $4,500 in executive compensation and $137 in general and administrative expenses.  The increase in operating expenses was due primarily to the increase in professional fees related to ongoing SEC filing obligations. We also recorded the $605,437 loss on the conversion of the Note by a related party.  These factors resulted in a net loss for the nine-month period ended

9

September 30, 2015 in the amount of $628,892 ($2.91 per share), compared to net loss of $19,602 ($0.40 per share) for the nine-month period ended September 30, 2014.

Liquidity and Capital Resources

Total assets at September 30, 2015 were $164 in cash, compared to $502 in cash at December 31, 2014. Total liabilities at September 30, 2015 were $95,539, consisting of $66,901 in accounts payable and accrued expenses, and $28,638 in related-party payables. At December 31, 2014, total liabilities were $121,485, consisting of $61,053 in accounts payable and accrued expenses, $2,380 in accounts payable to related parties, and $58,052 in related-party payables.

Because we currently have no revenues and limited available cash, for the immediate future we believe we will have to rely on potential advances from stockholders to continue to implement our business activities. There is no assurance that our stockholders will continue indefinitely to provide additional funds or pay our expenses.   It is likely the only other source of funding future operations will be through the private sale of our securities, either equity or debt.  

At September 30, 2015, we had stockholders’ deficit of $95,375 compared to stockholders’ deficit of $120,983 at December 31, 2014.  The increased deficit is primarily due to the net loss of $628,892 which is partially offset by $4,500 in contributed officer services during the nine-month period ended September 30, 2015.

Plan of Operation

Following the sale of patents, patent applications and technologies to Grünenthal, we have endeavored to explore possible plans for the remaining patents and new generation drug delivery technologies acquired in 2010. However, without adequate personnel with the requisite scientific expertise, we believe it will be difficult to further develop the technologies. As of this date no final decision has been reached regarding the patents and technology. Following the acquisition of Claims in September 2014, we believe that the company will most likely focus on the initial exploration of the acquired properties to determine whether there is commercial potential. We are now in the process of developing a definitive plan for the initial exploration of our Claims.

We are classified or considered an exploration stage mining company, which is defined as a company engaged in the search for mineral deposits or reserves of precious and base metal targets, which are not in either the development or production stage. We have no known mineral reserves on our properties and our proposed preliminary studies of the Claims is intended to be exploratory in nature.

Our current plan is to finalize and initiate an exploration program, to identify our objectives and anticipated growth for the next 12 months, and identify our cash requirements to fulfill our business objectives.  We will need to raise additional funds during the next 12 months to complete our exploration commitments and to pay for general business and operating expenses. We estimate that we will need up to $75,000 during the next twelve months to facilitate an exploration program. Management plans to explore a possible private placement of our securities and/or debt financing to raise the additional fund, although no definitive plan has been formulated and there can be no assurance that we will be able to realize the necessary funds.

If exploration results do not warrant drilling or further exploration, we will most likely suspend operations on the property. In that event, we would need to seek additional exploration properties and additional funding with which to conduct the work. If we are unable to obtain additional financing or additional properties, we may not be able to continue active business operations.

If we are able to complete an initial exploration programs and successfully identify a mineral deposit, we will need substantial additional funds for drilling and engineering studies to determine whether any identified mineral deposit is commercially viable. If we are unable to raise additional funds for this work or secure a strategic partner, we would be unable to proceed, even if a mineral deposit is discovered and is believed to be commercially viable.

Management believes that we will not be able to exist indefinitely without securing additional operating funds. In the view of our independent auditors, we will require additional funds to maintain operations and these conditions raise substantial doubt about our ability to continue as a going concern.

We do not anticipate conducting any product research or development over the next 12 months. Also, we do not expect to make any major equipment purchasers or make any significant capital expenditures in the immediate future unless we have the necessary funds. We do not have employees and do not expect to add employees over the next 12 months, except for part-time clerical assistance on an as-needed basis and possibly engaging outside advisors or consultants as requisite funds are available. We anticipate that our current management team will satisfy our everyday operating requirements for the foreseeable future.

10

Because we currently have limited cash, it may be necessary for officers, directors or stockholders to advance funds and we will most likely accrue expenses until a funding can be accomplished. Management intends to hold expenses to a minimum and to obtain services on a contingency basis when possible.  Further, we expect directors to defer any compensation until such time as we have sufficient funds.  We have not yet entered into any arrangements or definitive agreements to use outside advisors or consultants or to raise any capital.  

Because we currently have no revenues, most likely the only source of funding these expenses will be through the private sale of securities, either equity or debt. We are currently exploring possible funding sources, but we have not entered into any arrangements or agreements for funding as of this time. If we are unable to raise the necessary funding, our research and development plans will be delayed indefinitely. There can be no assurance that we will be able to raise the funds necessary to carry out our business plan on terms favorable to the company, or at all.

Net Operating Loss

We have accumulated approximately $2,713,179 of net operating loss carryforwards as of December 31, 2014.  This loss carry forward may be offset against taxable income and income taxes in future years and expires starting in the year 2014 through 2034.  The use of these losses to reduce future income taxes will depend on the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards.  In the event of certain changes in control, there will be an annual limitation on the amount of net operating loss carryforwards that can be used.  No tax benefit has been reported in the financial statements for fiscal years ended December 31, 2014 and 2013 or the nine months ended September 30, 2015, because it has been fully offset by a valuation reserve.  The use of future tax benefit is undeterminable because we have not started full operations.

Inflation

In the opinion of management, inflation has not and will not have a material effect on our operations in the immediate future.  Management will continue to monitor inflation and evaluate the possible future effects of inflation on our business and operations.

Off-balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3.               Quantitative and Qualitative Disclosures About Market Risk.

This item is not required for a smaller reporting company.

Item 4.              Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.  Disclosure controls and procedures (as defined in Rules  13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.  Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and principal accounting officer, to allow timely decisions regarding required disclosures.

As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures.  In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.  Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives.  Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment.  Based on the evaluation described above, management, including our principal executive officer and principal accounting officer, has concluded that, as of September 30, 2015, our disclosure controls and procedures were not effective.

Changes in Internal Control Over Financial Reporting.  Management has evaluated whether any change in our internal control over financial reporting occurred during the first three quarters of fiscal 2015. Based on its evaluation, management, including the chief executive officer and principal accounting officer, has concluded that there has been no change in our internal control over financial reporting during the first three quarters of fiscal 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

11

PART  II   —   OTHER INFORMATION

Item 1.           Legal Proceedings

There are no material pending legal proceedings to which we are a party or to which any of our property is subject and, to the best of our knowledge, no such actions against us are contemplated or threatened.

Item 1A.        Risk Factors

This item is not required for a smaller reporting company.

Item 2.           Unregistered Sales of Equity Securities and Use of Proceeds

This Item is not applicable.

Item 3.           Defaults Upon Senior Securities

This Item is not applicable.

Item 4.

Mine Safety Disclosures

This Item is not applicable.

Item 5.           Other Information

This Item is not applicable.

Item 6.           Exhibits

	Exhibit 31.1		Certification of C.E.O. and Acting Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.1		Certification of C.E.O. and Acting Principal Accounting Officer to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

            Exhibit 101*

Interactive Data File

*

In accordance with Rule 406T of Regulation S-T, these XBRL (eXtensible Business Reporting Language) documents are furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

12

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Protect Pharmaceutical Corporation
Date: November 16, 2015	By:	/S/GEOFF WILLIAMS
		Geoff Williams
		President, C.E.O. and Director Acting Principal Accounting Officer

13